1. bookVolume 24 (2016): Issue 2 (June 2016)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Pre-treatment antinuclear antibody positivity, therapeutic efficacy and persistence of biologics in rheumatoid arthritis

Published Online: 28 Jun 2016
Page range: 212 - 222
Received: 15 Oct 2015
Accepted: 03 Apr 2016
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Introduction: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are poor prognostic factors in rheumatoid arthritis (RA). The therapeutic implication of antinuclear antibody (ANA) positivity in RA is still debated. The study aims to evaluate ANA positivity as a prognostic factor for the therapeutic response to biologics in RA.

Methods: observational study; data were gathered from the Romanian Registry of Rheumatic Diseases which comprises all biological-treated RA patients in Romania. We included only RA patients who were tested for ANA before initiating biologics.

Results: A number of 740 RA patients were included (72.4% treated with TNF-α blockers, 27.6% with rituximab). Compared to ANA-negative patients, ANA-positive patients (26.9%) had: a higher disease activity score (DAS28) prior to biologics, at the time of treatment switch and after the observation period; lower drug persistence (p < 0.001 for all tests). Multiple linear regressions showed that ANA positivity is a significant predictor of the current value of DAS28, independently of the presence of RF and/or ACPA (p < 0.05).

Conclusion: ANA positivity in RA patients before starting biologics may be a poor prognosis factor for efficacy and drug persistence. Further studies are needed to confirm these observations.

Keywords

1. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21(3):613-9. DOI: 10.1016/0270-9139(95)90507-3 DOI: 10.1002/hep.1840210302.10.1016/0270-9139(95)90507-3Search in Google Scholar

2. Bonnet F, Pineau JJ, Taupin JL, Feyler A, Bonarek M, de WS, et al. Prevalence of cryoglobulinemia and serological markers of autoimmunity in human immunodeficiency virus infected individuals: a cross-sectional study of 97 patients. JRheumatol. 2003;30(9):2005-10.Search in Google Scholar

3. Imran A, Neelam F, Tariq M. Incidence of circulating antinuclear antibodies in cancer patients. Indian JMedSci. 2003;57(3):113-6.Search in Google Scholar

4. Qadan LR, Ahmed AA, Abdel-Jalil S, Al-Bader MA. Significance of antinuclear antibodies and rheumatoid factor in patients with advanced peripheral arterial disease. MedPrincPract. 2010;19(3):192-5. DOI: 10.1159/000273071.10.1159/000273071Search in Google Scholar

5. Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH. Antinuclear antibodies in primary pulmonary hypertension. JAmCollCardiol. 1986;8(6):1307-11. DOI: 10.1016/s0735-1097(86)80301-1.10.1016/S0735-1097(86)80301-1Search in Google Scholar

6. Yukawa N, Fujii T, Kondo-Ishikawa S, Yoshifuji H, Kawabata D, Nojima T, et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis ResTher. 2011;13(6):R213. DOI: 10.1186/ar3546.10.1186/ar3546333466622192852Search in Google Scholar

7. Nisihara R, Kubis MM, Rodrigues PC, Skare T, Mocelin V, Utiyama S. Antinuclear antibodies and rheumatoid factor positivity in healthy elderly adults: a cross-sectional study in 336 individuals. JAmGeriatrSoc. 2013;61(11):2044-6. DOI: 10.1111/jgs.12533.10.1111/jgs.1253324219209Search in Google Scholar

8. Nishimura S, Nishiya K, Hisakawa N, Chikazawa H, Ookubo S, Nakatani K, et al. Positivity for antinuclear antibody in patients with advanced rheumatoid arthritis. Acta MedOkayama. 1996;50(5):261-5.Search in Google Scholar

9. Muzellec Y, Le GP, Jouquan J, Fauquert P, Muller S, Youinou P. Antibodies to histones in rheumatoid arthritis. DiagnClinImmunol. 1988;5(6):326-31.Search in Google Scholar

10. Glossop JR, Dawes PT, Mattey DL. Antinuclear antibodies are associated with tumor necrosis factor receptor I gene polymorphism in patients with rheumatoid arthritis. ClinExpRheumatol. 2011;29(4):609-15.Search in Google Scholar

11. Jacobsen S. Young age of onset is associated with increased prevalence of circulating IgM rheumatoid factor and antinuclear antibodies at presentation in women with rheumatoid arthritis. ClinRheumatol. 2004;23(2):121-2. DOI: 10.1007/s10067-003-0844-9.10.1007/s10067-003-0844-915045625Search in Google Scholar

12. Caspi D, Elkayam O, Eisinger M, Vardinon N, Yaron M, Burke M. Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease. RheumatolInt. 2001;20(2):43-7. DOI: 10.1007/ s002960000073.10.1007/s00296000007311269531Search in Google Scholar

13. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. BestPractResClinRheumatol. 2007;21(5):907-27. DOI: 10.1016/j.berh.2007.05.007.10.1016/j.berh.2007.05.00717870035Search in Google Scholar

14. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. AnnRheumDis. 2014;73(3):492-509. DOI: 10.1136/annrheumdis-2013-204573.10.1136/annrheumdis-2013-204573393307424161836Search in Google Scholar

15. Jilani AA, Mackworth-Young CG. The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. IntJRheumatol. 2015;2015:728610. DOI: 10.1155/2015/728610.10.1155/2015/728610436437025821469Search in Google Scholar

16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. AnnRheumDis. 2010;69(9):1580-8. DOI: 10.1002/art.27584 DOI: 10.1136/ard.2010.138461.10.1002/art.2758420872595Search in Google Scholar

17. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum. 1995;38(1):44-8. DOI: 10.1002/ art.1780380107.10.1002/art.17803801077818570Search in Google Scholar

18. Innala L, Berglin E, Moller B, Ljung L, Smedby T, Sodergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis research & therapy. 2014;16(2):R94. DOI: 10.1186/ar4540.10.1186/ar4540406026324731866Search in Google Scholar

19. Amaya-Amaya J, Calixto OJ, Saade-Lemus S, Calvo- Paramo E, Mantilla RD, Rojas-Villarraga A, et al. Does non-erosive rheumatoid arthritis exist? A cross-sectional analysis and a systematic literature review. Seminars in arthritis and rheumatism. 2015;44(5):489-98. DOI: 10.1016/j.semarthrit.2014.09.006.10.1016/j.semarthrit.2014.09.00625440525Search in Google Scholar

20. Rodriguez-Carrio J, Alperi-Lopez M, Lopez P, Alonso- Castro S, Ballina-Garcia FJ, Suarez A. Angiogenic T cells are decreased in rheumatoid arthritis patients. Annals of the rheumatic diseases. 2015;74(5):921-7. DOI: 10.1136/annrheumdis-2013-204250.10.1136/annrheumdis-2013-20425024399233Search in Google Scholar

21. Mathieu S, Couderc M, Pereira B, Soubrier M. The effects of TNF-alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: a meta-analysis. Seminars in arthritis and rheumatism. 2013;43(3):e1-2. DOI: 10.1016/j.semarthrit.2013.05.005.10.1016/j.semarthrit.2013.05.00523810615Search in Google Scholar

22. Hsue PY, Scherzer R, Grunfeld C, Imboden J, Wu Y, Del Puerto G, et al. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. Journal of the American Heart Association. 2014;3(5):e001267. DOI: 10.1161/JAHA.114.001267.10.1161/JAHA.114.001267432382725336464Search in Google Scholar

23. Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V, et al. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. BioMed research international. 2014;2014:368681. DOI: 10.1155/2014/368681.10.1155/2014/368681405537824967362Search in Google Scholar

24. Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus erythematosus. CurrOpinRheumatol. 2004;16(5):534-40. DOI: 10.1097/01. bor.0000135452.62800.8f.10.1097/01Search in Google Scholar

25. Smeenk RJ. Antinuclear antibodies: cause of disease or caused by disease? Rheumatology(Oxford). 2000;39(6):581-4. DOI: 10.1093/rheumatology/39.6.581.10.1093/rheumatology/39.6.58110888701Search in Google Scholar

26. Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A. One year in review: the pathogenesis of rheumatoid arthritis. Clinical and experimental rheumatology. 2015;33(4):551-8.Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo